What is it about?
The growth and proliferative of myeloid leukemia cells depends on several biochemical pathways in the cells. FLT3 in one of the key proteins in the pathway that leads to leukemia growth. We discuss the current stage of knowledge of FLT3 inhibitor including the published clinical studies, preliminary results presented at major hematology and oncology meetings, and ongoing clinical studies in this area. Our subtopics are focused to each clinical scenario, including newly diagnosed leukemia, relapsed and/or refractory setting, and maintenance therapy. We also summarize selected studies of FLT3 inhibitors that got published or their preliminary results presented in a comprehensive table.
Featured Image
Why is it important?
This will pave the way of getting to understand the background and current knowledge of FLT3 inhibitors in treatment of acute myeloid leukemia in each clinical setting.
Perspectives
After several decades, we just have a new treatment approved into frontline treatment of acute myeloid leukemia, a disease that still has poor outcome overall. Aiming at FLT3, one of the poor prognostic markers, seems to be promising so far and several active scientific and clinical studies are underway to help improving the outcomes of these patients. I hope that, with my work and attempt to be concise and comprehensive on the works of FLT3 inhibitors, reader will get to know the current status of this particular group of agents and ready for possible new approval of many more FLT3 inhibitors.
Grerk Sutamtewagul
University of Iowa Hospitals and Clinics
Read the Original
This page is a summary of: Clinical use of FLT3 inhibitors in acute myeloid leukemia, OncoTargets and Therapy, October 2018, Dove Medical Press,
DOI: 10.2147/ott.s171640.
You can read the full text:
Contributors
The following have contributed to this page
